Answers are grounded in this paper and cite their sources.
Background The purpose of nephrectomy after immune checkpoint inhibitor (ICI)-based combination therapy differs between metastatic (M1) and M0 locally advanced renal cell carcinoma (RCC). Postoperative management after no evidence of disease (NED) is uncertain. We described selection, surgical intent, perioperative and pathologic outcomes, and postoperative management. Methods We retrospectively reviewed patients starting first-line ICI-based combination therapy for M1 or M0 locally advanced RCC at our center from September 2018 to January 2026. The surgical series included patients with an intact primary tumor who subsequently underwent nephrectomy; nonoperative patients were summarized separately. Analyses were descriptive. Results Of 54 patients, 27 had an intact primary tumor; nine underwent 10 nephrectomy procedures (M1, n = 5; M0, n = 4), and 18 did not. Nonoperative selection was largely associated with progressive disease or insufficient downstaging; two near-complete responders did not undergo radical nephrectomy because nephron-sparing surgery was infeasible and renal preservation was prioritized. In M1 disease, deferred cytoreductive nephrectomy aimed to achieve NED after metastatic complete response in three and control the residual primary tumor in two. In M0 disease, deferred nephrectomy had definitive intent after multidisciplinary reassessment. All 10 resections were R0; two required transfusion, one was converted from laparoscopic to open surgery, and none had perioperative complications. One specimen was ypT0. Seven achieved postoperative NED, although six had viable tumor in the resected specimen. All three M1 patients with NED restarted nivolumab. After final nephrectomy, three of four M0 patients received no RCC-directed therapy; one restarted nivolumab for melanoma. During a median postoperative follow-up of 9.5 months for the entire cohort (range, 1.3–54.6 months), no RCC recurrence was documented among the seven patients with NED; however, follow-up for the three M0 patients without RCC-directed therapy was only 1.3–9.5 months. Conclusions This descriptive case series illustrates different surgical objectives and postoperative pathways in M1 and M0 RCC. The small, highly selected cohort, absence of a comparator group, and short follow-up preclude conclusions about the benefit of nephrectomy, the safety of stopping systemic therapy, or criteria for postoperative treatment.
No takes yet. Share an insight, caveat, or question.
Furubayashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: